Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone for Prevention and Treatment of OHSS
NCT04351126Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2019
- Primary completion
- Feb 2020
- Countries
- 1
- Sponsor
- Ganin Fertility Center
- Modality
- Orthosteric Ligands
- Drugs
- fludrocortisone
- Conditions
- ovarian hyperstimulation syndrome (OHSS)
01
Overview
Phase 2, randomised, open-label trial of fludrocortisone in ovarian hyperstimulation syndrome (OHSS), sponsored by Ganin Fertility Center. Primary endpoints: Duration of recovery at 10 days and Prevention of OHSS occurrence at 21 days. Started Apr 2019; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Patients undergoing ICSI at risk of OHSS (PCO, history of OHSS, high AMH, or high E2 levels).
04
Endpoints
Primary
Duration of recovery
Prevention of OHSS occurrence
Beyond the preview
Go deeper on NCT04351126.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351126.